Terms: = Ovarian cancer AND PTPRB, ENSG00000127329, 5787, MGC142023, DKFZp686H15164, MGC59935, PTPB, HPTP-BETA, P23467, HPTPB, R-PTP-BETA, FLJ44133, DKFZp686E2262
2 results:
1. Patterns of Müllerian Inhibiting Substance Type II and Candidate Type I Receptors in Epithelial ovarian cancer.
Basal E; Ayeni T; Zhang Q; Langstraat C; Donahoe PK; Pepin D; Yin X; Leof E; Cliby W
Curr Mol Med; 2016; 16(3):222-31. PubMed ID: 26917267
[TBL] [Abstract] [Full Text] [Related]
2. A comparative evaluation of the ability of serum CA 125, CA 19-9, CA 15-3, CA 50, CA 72-4 and TATI assays in reflecting the course of disease in patients with ovarian carcinoma.
Gadducci A; Ferdeghini M; Ceccarini T; Prontera C; Facchini V; Bianchi R; Fioretti P
Eur J Gynaecol Oncol; 1990; 11(2):127-33. PubMed ID: 2379512
[TBL] [Abstract] [Full Text] [Related]